# Catalent, Inc. – Consensus ‘hold’ rating and 48.1% Upside Potential

- Link: https://www.directorstalkinterviews.com/catalent-inc.consensus-hold-rating-and-48.1-upside-potential/4121131758
- Published: 2023-11-01T14:49:54+00:00
- Author: Charlotte Edwards

**Catalent, Inc.** which can be found using ticker (CTLT) have now 14 confirmed 
analysts covering the stock with the consensus suggesting a rating of ‘hold’. The
target price High/Low ranges between $58.00 and $44.00 calculating the mean target
price we have $50.93. Given that the stocks previous close was at $34.39 and the
analysts are correct then we can expect a percentage increase in value of 48.1%.
It’s also worth noting that there is a 50 day moving average of $45.46 and the 200
day MA is $50.07. The market cap for the company is 6.12B. The stock price is currently
at: $33.94 USD

 The potential market cap would be $9,061,113,773 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of -, revenue per share of $23.62 and
a 0.43% return on assets.

Catalent, Inc. is a provider of development and manufacturing solutions for drug,
cell and gene therapies biologics, vaccines, and consumer health products. The Company’s
segments include Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery,
and Clinical Supply Services. Its Biologics segment provides development and manufacturing
for protein, plasmid DNA mRNA, cell therapy, viral vaccines and viral-based gene
therapies. Its Softgel and Oral Technologies segment provide formulation, development,
and manufacturing services for soft capsules, as well as large-scale manufacturing
of oral solid dose forms. Its Oral and Specialty Delivery segment provides formulation
development and manufacturing across a range of technologies along with integrated
downstream clinical development and commercial supply solutions. Its Clinical Supply
Services segment provides manufacturing, packaging, storage, distribution, and inventory
management for, drugs, biologics and clinical trials.

Share on: